Despite the loss of the live attenuated influenza vaccine, overall immunization rates in children 2-17 remained steady.
The majority of healthcare workers receive an influenza vaccination, but more pregnant women should be vaccinated.
The CDC continues to urge pregnant women to receive influenza vaccinations.
Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.
Influenza vaccine in the prior season did not decrease the efficacy of the current season's vaccine.
The American Academy of Pediatrics recommends against the use of the quadrivalent live attenuated influenza vaccine (LAIV4).
Researchers examined the efficacy of digital immunoassays vs rapid influenza diagnostic tests for diagnosing influenza.
Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.
Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.
The influenza A virus in swine was transmitted to humans at state fairs in Ohio and Michigan.
The Advisory Committee on Immunization Practices (ACIP) has issued the 2017-2018 influenza vaccination guidelines.
The rs34481144 risk allele may serve as a genetic marker for identifying individuals at increased risk for severe influenza infection.
Data from the 2015-2016 season shows that the live attenuated influenza vaccine was ineffective among children ages 2-17.
Influenza and pulmonary-related hospitalizations were lower in elderly patients who received the high-dose trivalent influenza vaccine vs the standard dose.
Increasing Vitamin D supplements does not prevent winter upper respiratory tract infections in young healthy children.
Influenza vaccination provided a small protective effect in patients with asthma.
Vaccinations include Fluad, Flucelvax Quadrivalent, Afluria Quadrivalent, and Fluvirin,
During the 2015-2016 flu season, approximately 59.3% of children and 41.7% of adults received the influenza vaccine.
The 2016-2017 flu season is the first time since 2014-2015 that pediatric influenza-associated deaths have surpassed 100.
Researchers assessed the relative risk for developing influenza or influenza-like illness based on study participants BMI.
Right-sided abdominal pain, vomitting, fever, and mild diarrhea were all present in a 66-year-old woman with a history of sarcoidosis and hypertension.
Immunogenicity of 4 different vaccine strains, including H1N1, H3N2, and B influenza, were examined.
Videotapes of 50 visits were examined to determine whether clinician pursuit of influenza vaccine affected vaccination rates in pediatric patients.
Over 2278 health subjects were included in a multicenter study of the Seqirus IIV4 quadrivalent inactivated influenza vaccine.
Molecular point-of-care testing for viruses led to more patients receiving single or brief doses of antibiotics without any evidence of increased harm.
A new study found no risks for exacerbation of asthma in children given LAIV, despite ACIP recommendations against its use in children with asthma.
The inactivated monovalent influenza A(H1N1) vacccines in both adjuvanted and unadjuvanted forms were more effective in children than adults.
Birth weight and week's gestation of infants at birth are not affected by maternal influenza vaccination during any trimester of pregnancy.
Intravenous zanamivir is as safe and effective as oral oseltamivir when used in patients with severe influenza.
No safety signals were observed with the administration of quadrivalent live attenuated influenza vaccine, according to a large population study.
Researchers evaluated whether administering double-dose IIV4 to children younger than 3 years of age improved protection against influenza B without increasing adverse events in a phase 3 trial.
The live attenuated influenza vaccine, LAIV, is safe in children under 2 with underlying medical conditions.